<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680417</article-id><article-id pub-id-type="doi">10.3390/v16121953</article-id><article-id pub-id-type="publisher-id">viruses-16-01953</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genetic Diversity and Antiretroviral Resistance in HIV-1-Infected Patients Newly Diagnosed in Cabo Verde</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4567-1097</contrib-id><name><surname>Leal</surname><given-names>Silv&#x000e2;nia Da Veiga</given-names></name><xref rid="af1-viruses-16-01953" ref-type="aff">1</xref><xref rid="af2-viruses-16-01953" ref-type="aff">2</xref><xref rid="c1-viruses-16-01953" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6390-4128</contrib-id><name><surname>Pimentel</surname><given-names>Victor</given-names></name><xref rid="af2-viruses-16-01953" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1009-6715</contrib-id><name><surname>Gon&#x000e7;alves</surname><given-names>Paloma</given-names></name><xref rid="af3-viruses-16-01953" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7766-1059</contrib-id><name><surname>Monteiro de Pina Ara&#x000fa;jo</surname><given-names>Isabel In&#x000ea;s</given-names></name><xref rid="af4-viruses-16-01953" ref-type="aff">4</xref><xref rid="af5-viruses-16-01953" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4832-9898</contrib-id><name><surname>Parreira</surname><given-names>Ricardo</given-names></name><xref rid="af2-viruses-16-01953" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0176-5585</contrib-id><name><surname>Taveira</surname><given-names>Nuno</given-names></name><xref rid="af3-viruses-16-01953" ref-type="aff">3</xref><xref rid="af6-viruses-16-01953" ref-type="aff">6</xref><xref rid="fn1-viruses-16-01953" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7928-3087</contrib-id><name><surname>Pingarilho</surname><given-names>Marta</given-names></name><xref rid="af2-viruses-16-01953" ref-type="aff">2</xref><xref rid="fn1-viruses-16-01953" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3903-5265</contrib-id><name><surname>Abecasis</surname><given-names>Ana B.</given-names></name><xref rid="af2-viruses-16-01953" ref-type="aff">2</xref><xref rid="fn1-viruses-16-01953" ref-type="author-notes">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Hizi</surname><given-names>Amnon</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Foley</surname><given-names>Brian T.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01953"><label>1</label>Instituto Nacional de Sa&#x000fa;de P&#x000fa;blica de Cabo Verde, Largo do Desastre da Assist&#x000ea;ncia, Ch&#x000e3; de Areia, Praia CP 7943-010, Cape Verde</aff><aff id="af2-viruses-16-01953"><label>2</label>Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, Rua da Junqueira 100, 1349-008 Lisboa, Portugal</aff><aff id="af3-viruses-16-01953"><label>3</label>Research Institute for Medicines (iMed.ULisboa), Faculdade de Farm&#x000e1;cia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal</aff><aff id="af4-viruses-16-01953"><label>4</label>Faculdade de Ci&#x000ea;ncias e Tecnologia, Universidade de Cabo Verde, Campus do Palmarejo Grande, Praia CP 7943-010, Cape Verde</aff><aff id="af5-viruses-16-01953"><label>5</label>One Health Research Center&#x02014;Cabo Verde (NEST-CV), Universidade de Cabo Verde, Campus do Palmarejo Grande, Praia CP 7943-010, Cape Verde</aff><aff id="af6-viruses-16-01953"><label>6</label>Centro de Investiga&#x000e7;&#x000e3;o Interdisciplinar Egas Moniz (CiiEM), Egas Moniz School of Health &#x00026; Science, Quinta da Granja, Monte de Caparica, 2829-511 Almada, Portugal</aff><author-notes><corresp id="c1-viruses-16-01953"><label>*</label>Correspondence: <email>silvania.leal@insp.gov.cv</email></corresp><fn id="fn1-viruses-16-01953"><label>&#x02020;</label><p>Shared last authors.</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1953</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>06</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The high genetic variability of HIV-1 and the emergence of transmitted drug resistance (TDR) can impact treatment efficacy. In this study, we investigated the prevalent HIV-1 genotypes and drug-resistance-associated mutations in drug-na&#x000ef;ve HIV-1 individuals in Cabo Verde. The study, conducted between 2018 and 2019, included drug-na&#x000ef;ve HIV-1 individuals from the S&#x000e3;o Vicente, Boa Vista, Fogo, and Santiago islands. The HIV-1 <italic toggle="yes">pol</italic> gene was sequenced using Sanger sequencing. TDR was identified using the Stanford Calibrated Population Resistance tool, and resistance levels to different drugs were interpreted with the Stanford HIV database. The genetic diversity of HIV-1 was determined through phylogenetic analysis, and epidemiological and behavioural data were collected via questionnaires. Of the 73 participants, the majority were male (52.1%). The CRF02_AG recombinant form predominated (41.1%), followed by subtype G (37.0%). The overall prevalence of TDR was 9.6%. Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations occurred in 2.7% of individuals, while Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) mutations occurred in 9.6%. The most prevalent mutations were K103N (5.5%) and M184V (2.7%). No protease- or integrase-associated mutations were found. The high levels of resistance to NNRTIs found demonstrate the need for surveillance of resistance mutations to ensure the efficacy and durability of the current therapeutic regimen, which includes Dolutegravir.</p></abstract><kwd-group><kwd>transmitted drug resistance</kwd><kwd>HIV-1 subtypes</kwd><kwd>genetic diversity</kwd><kwd>genomic surveillance</kwd><kwd>Cabo Verde</kwd></kwd-group><funding-group><award-group><funding-source>Millennium BCP Foundation</funding-source></award-group><award-group><funding-source>Cam&#x000f5;es I.P.</funding-source></award-group><award-group><funding-source>Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia</funding-source><award-id>PTDC/SAU-PUB/4018/2021</award-id><award-id>PTDC/SAU-INF/31990/2017</award-id><award-id>PTDC/DTP-EPI/7066/2014</award-id><award-id>UID/04413/2020</award-id></award-group><award-group><funding-source>Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia (FCT)</funding-source></award-group><award-group><funding-source>Aga Khan Development Network (AKDN)</funding-source><award-id>332821690</award-id></award-group><funding-statement>This work received funding from the Millennium BCP Foundation and Cam&#x000f5;es I.P., which granted the scholarship to Silv&#x000e2;nia Leal; and from Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia through projects MARVEL&#x02014;FCT PTDC/SAU-PUB/4018/2021, Integriv&#x02014;PTDC/SAU-INF/31990/2017, MigrantHIV&#x02014;PTDC/DTP-EPI/7066/2014, and GHTM&#x02014;FCT GHTM&#x02014;UID/04413/2020. This research was also funded by Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia (FCT) and Aga Khan Development Network (AKDN)&#x02014;Portugal Collaborative Research Network in Portuguese-speaking countries in Africa (Project reference: 332821690).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01953"><title>1. Introduction</title><p>Human immunodeficiency virus (HIV) infection remains a major global public health issue. By the end of 2022, approximately 39 million people were living with HIV, with 1.3 million new infections and 29.8 million people receiving antiretroviral therapy (ART) [<xref rid="B1-viruses-16-01953" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01953" ref-type="bibr">2</xref>]. ART has significantly reduced morbidity and mortality in people living with HIV [<xref rid="B3-viruses-16-01953" ref-type="bibr">3</xref>]. However, the high genetic variability of HIV-1 can lead to the selection of antiretroviral drug resistance mutations [<xref rid="B4-viruses-16-01953" ref-type="bibr">4</xref>]. Drug-resistant HIV variants can be transmitted to treatment-na&#x000ef;ve individuals and further spread throughout the population over time [<xref rid="B5-viruses-16-01953" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01953" ref-type="bibr">6</xref>]. Transmitted drug resistance (TDR) results from infection with an HIV-1 strain containing one or more resistance-associated mutations [<xref rid="B7-viruses-16-01953" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01953" ref-type="bibr">8</xref>]. Several studies have described the prevalence of TDR in treatment-na&#x000ef;ve patients, which varies by geographic region. Studies in the United States and Europe have shown that the prevalence of TDR ranges from 5 to 15% [<xref rid="B9-viruses-16-01953" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01953" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01953" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01953" ref-type="bibr">12</xref>]. However, in countries with limited resources, where data are scarce, some reports describe an exponential increase in TDR prevalence, and many exceed 10% of TDR prevalence [<xref rid="B13-viruses-16-01953" ref-type="bibr">13</xref>].</p><p>Cabo Verde is an archipelago of ten islands, located in the Atlantic Ocean, 445 km from the coast of West Africa, with a population of approximately 491,233 [<xref rid="B14-viruses-16-01953" ref-type="bibr">14</xref>]. The prevalence of HIV-1 infection was about 0.6% in 2018, with higher rates among women (0.7%) than among men (0.3%) [<xref rid="B15-viruses-16-01953" ref-type="bibr">15</xref>]. HIV-1 is the predominant type of HIV in the country, with a prevalence of 0.46%, being significantly more common than HIV-2, which has a much lower prevalence [<xref rid="B16-viruses-16-01953" ref-type="bibr">16</xref>].</p><p>ART in Cabo Verde began in 2004, following the recommendations of the World Health Organization (WHO). Since then, antiviral medications have been provided free of charge, and treatment is initiated as early as possible following an HIV infection diagnosis [<xref rid="B17-viruses-16-01953" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01953" ref-type="bibr">18</xref>]. In recent years, HIV treatment guidelines have been significantly updated, reflecting ongoing advances in the field [<xref rid="B18-viruses-16-01953" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01953" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01953" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01953" ref-type="bibr">21</xref>]. In 2018, WHO introduced dolutegravir (DTG) as the preferred choice in first- and second-line therapeutic regimens for people living with HIV-1. This change was made due to the increasing resistance to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), which were replaced by DTG [<xref rid="B21-viruses-16-01953" ref-type="bibr">21</xref>,<xref rid="B22-viruses-16-01953" ref-type="bibr">22</xref>]. The most recent national guidelines for ART in adults and adolescents living with HIV-1 in Cabo Verde date from 2019 [<xref rid="B17-viruses-16-01953" ref-type="bibr">17</xref>] and incorporate WHO recommendations, including the initiation of antiretroviral therapy for all people living with HIV (PLHIV), regardless of CD4 cell count. Additionally, the guidelines address ideal treatment regimens and the management of HIV coinfection with opportunistic infections. Accordingly, DTG was introduced as the first-line drug in a regimen combining two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and one integrase strand transfer inhibitor (INSTI) [<xref rid="B21-viruses-16-01953" ref-type="bibr">21</xref>].</p><p>The data on the molecular epidemiology of drug resistance mutations (DRMs) and HIV-1 genotypes circulating in Cabo Verde are limited. However, some studies have already identified HIV-1 subtypes such as G, F, B, C, and A, as well as recombinant forms CRF02_AG, CRF01_AG, CRF02_AE, and CRF05_DF and complex recombinant forms. These studies also report that DRMs were also identified in the protease (PR) and Reverse Transcriptase (RT) of treated and na&#x000ef;ve patients [<xref rid="B23-viruses-16-01953" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01953" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01953" ref-type="bibr">25</xref>]. Previous studies involving untreated patients are outdated, with the most recent research focusing exclusively on treated individuals. This highlights the need for updated research on HIV-1 genotypes and resistance profiles. Our study aims to address this gap by investigating the most prevalent HIV-1 genotypes and drug resistance mutations in newly diagnosed and drug-na&#x000ef;ve individuals in Cabo Verde.</p></sec><sec id="sec2-viruses-16-01953"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01953"><title>2.1. Study Population and Sample Collection</title><p>Drug-na&#x000ef;ve individuals diagnosed with HIV-1 between 2018 and 2019 on 4 different islands of Cabo Verde (S&#x000e3;o Vicente, Boa Vista, Fogo, and Santiago) were included in this study. A semi-structured questionnaire was used to collect data on demographic, socioeconomic, behavioural, and clinical characteristics of the patients through face-to-face interviews and from the participants&#x02019; medical records. Written informed consent was obtained from all participants after informing respondents of the aim of the study, potential risks and benefits of participation, and the rights of the participants. Blood samples were collected in EDTA tubes, and aliquots of plasma were stored at &#x02212;80 &#x000b0;C. Plasma samples were anonymized and transferred to Portugal for genotyping by population sequencing.</p></sec><sec id="sec2dot2-viruses-16-01953"><title>2.2. HIV Subtyping and Drug-Resistance Mutation Analyses</title><p>Viral RNA was extracted from HIV-1 plasma samples using the commercial kit QIAamp<sup>&#x000ae;</sup> Viral RNA Mini KIT (Qiagen, Hilden, Germany), according to the manufacturer&#x02019;s instructions. One-step reverse-transcription PCR (one-step RT-PCR) was performed for the PR, RT, and IN regions of the polymerase gene using the SuperScript III One-Step RT-PCR System with the PlatinumTM Taq DNA Polymerase kit from InvitrogenTM (Thermo Fisher Scientific, Carlsbad, CA, USA), following the manufacturer&#x02019;s protocol. Subsequently, nested PCR was conducted using the NZYTaq II DNA polymerase kit (NZYtech genes &#x00026; enzymes, Lisbon, Portugal), following the manufacturer&#x02019;s recommendations. Genotyping of the HIV-1 <italic toggle="yes">pol</italic> gene was performed using primers previously described [<xref rid="B25-viruses-16-01953" ref-type="bibr">25</xref>]. The PCR products were purified using the NucleoSpinR Gel and PCR Clean-Up (Macherey-Nagel, D&#x000fc;ren, Alemanha) following the manufacturer&#x02019;s protocol, and the nucleotide sequencing of the purified DNA fragments was performed by STAB VIDA (Oeiras, Portugal) by the You Tube It system, using the method described by Sanger et al. [<xref rid="B26-viruses-16-01953" ref-type="bibr">26</xref>]. Sequence electropherograms were visualized, assembled, and aligned using the bioinformatics software Geneious Prime (version 2022.0.1, Biomatters, Auckland, New Zealand), and the resulting consensus sequences were aligned with an HIV-1 reference sequence (B-HXB2-PRT_ 2253&#x02013;3700). Subtyping was performed using REGA v.3.0, Stanford HIV, and Comet software. To infer the phylogenetic relationships between the newly generated sequences, a maximum likelihood phylogenetic tree was constructed for the pol gene. The tree was constructed using all reference subtypes and subsubtypes, including the CRFs (01_AE and 02_AG). All sequences were manually aligned and adjusted using Virulign and AliView. Subsequently, a phylogenetic tree based on the general nucleotide substitution (GTR) model was constructed in FastTree (version 2.1.11). TDR mutations were identified using the Stanford Calibrated Population algorithm (<uri xlink:href="https://hivdb.stanford.edu/cpr/">https://hivdb.stanford.edu/cpr/</uri>, accessed on 28 July 2023). For measuring the clinical impact of DRMs, the Stanford Genotypic Resistance Interpretation Algorithm was used [<xref rid="B7-viruses-16-01953" ref-type="bibr">7</xref>,<xref rid="B11-viruses-16-01953" ref-type="bibr">11</xref>].</p></sec><sec id="sec2dot3-viruses-16-01953"><title>2.3. Statistical Analysis</title><p>Statistical analysis was performed with IBM SPSS 27.0 (Statistical Package for Social Sciences, Chicago, IL, USA). Data were analyzed using contingency tables with the chi-square test and Fisher&#x02019;s exact test. For statistical analysis, we considered a 5% significance level. A binary logistic regression model was used to examine the association between baseline demographic, clinical, socioeconomic, and behavioural factors and the occurrence of TDR mutations. The results are presented using Odds Ratios (ORs). Proportions and confidence intervals for proportions were calculated using the 95% Wilson Confidence Interval for binomially distributed data. </p></sec><sec id="sec2dot4-viruses-16-01953"><title>2.4. Ethics Approval and Consent to Participate</title><p>This study was reviewed and approved by the Ethical Committee of the Ministry of Health of Cabo Verde (Reference no. 13/2018) and by the National Data Protection Commission (reference no. 192/2018). The privacy and confidentiality issues had been secured throughout the processes.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01953"><title>3. Results</title><sec id="sec3dot1-viruses-16-01953"><title>3.1. Study Population Demographics and Clinic Characteristics</title><p>This study included 73 drug-na&#x000ef;ve PLHIV. When analyzing the sex distribution, we observed that 47.9% (n = 35) were female. The subtype distribution of the infecting strains in female patients was as follows: 15.1% (n = 11) belonged to the CRF02_AG recombinant form, 20.5% (n = 15) to subtype G, and 12.3% (n = 9) to other subtypes. Out of the 52.1% (n = 38) male participants, 26.0% (n = 19) were infected with the HIV-1 CRF02_AG recombinant form, 16.4% (n = 12) with subtype G, and 9.6% (n = 7) with other subtypes. The average age of the participants was 44.8 years (&#x000b1;14.8).</p><p>The age groups with the highest number of individuals (31&#x02013;40 years and 41&#x02013;50 years) were more frequently infected with the HIV-1 subtype G (13.7%; n = 10) and CRF02_AG recombinant form (12.3%; n = 9), respectively. The majority of participants resided on the island of Santiago (75.3%; n = 55), where more cases of infections with subtype G and the CRF02_AG recombinant form were found (32.9%, n = 24; 31.5%, n = 23, respectively), followed by other subtypes (11.0%, n = 8).</p><p>When analyzing participants stratified by island of residence, the island of residence was found to be significantly associated with viral subtype (<italic toggle="yes">p</italic> = 0.014). However, other demographic and clinical characteristics were not significantly associated with the viral subtypes/genetic recombinants. Within participants with TDR, the most common subtypes were the CRF02_AG recombinant form (5.5%; n = 4) and subtype G (4.4%; n = 3). <xref rid="viruses-16-01953-t001" ref-type="table">Table 1</xref> presents the demographic and clinical characteristics of the participants, stratified by the different viral subtypes.</p></sec><sec id="sec3dot2-viruses-16-01953"><title>3.2. Genetic Diversity of HIV-1 Subtypes</title><p>In total, six different HIV-1 subtypes were identified, including five pure subtypes and one circulating recombinant form (CRF02_AG). Phylogenetic analysis revealed that most cases (41%, n = 30) were caused by CRF02_AG strains, followed by subtype G (37%, n = 27), subtype B (10%, n = 7), subtype F (7%, n = 5), subtype A (4%, n = 3), and subtype C (1%, n = 1). No pattern suggestive of the transmission of TDR was observed in the phylogenetic analysis of the distribution of sequences carrying surveillance drug resistance mutations (SDRMs). The sequences containing SDRMs are marked with red dots on the graph, with most of these mutations observed in the CRF_02AG strains and subtype G, which are the predominant strains in the country (<xref rid="viruses-16-01953-f001" ref-type="fig">Figure 1</xref>).</p><p>The geographic distribution of HIV-1 subtypes in Cabo Verde varies between the islands. Santiago has the highest number of cases (n = 55), with a predominance of subtype G (43.6%, n = 24) and CRF02_AG (41.8%, n = 23). In S&#x000e3;o Vicente (n = 10), subtype F is the most prevalent (60%, n = 6), while Boavista (n = 4) only presents cases of CRF02_AG (50%, n = 2) and subtype G (50%, n = 2). On the island of Fogo (n = 4), cases are distributed among subtype B (25%, n = 1), CRF02_AG (50%, n = 2), and subtype G (25%, n = 1) (<xref rid="viruses-16-01953-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot3-viruses-16-01953"><title>3.3. Prevalence of HIV-1-Transmitted Drug Resistance</title><p>Of the 73 pol sequences analyzed, the overall prevalence of TDR was 9.6% (n = 7). Among the patients, mutations in RT conferring resistance to NRTIs were identified in 2.7% (n = 2), while resistance to NNRTIs was found in 9.6% (n = 7). No resistance mutations were found in PR and IN genes that confer resistance to protease inhibitors (PIs) or INSTIs, respectively. Single-class resistance mutations were found in 6.8% (n = 5) and dual-class resistance mutations to NRTIs + NNRTIs were found in 2.7% (n = 2) of the patients. No triple-class resistance mutations were found. No resistance was found for other combinations of drug classes (PIs + NRTIs, PIs + NNRTIs) (<xref rid="viruses-16-01953-f003" ref-type="fig">Figure 3</xref>).</p><p>Mutations were found conferring resistance to two classes of antiretroviral drugs: NNRTIs and NRTIs. For the NNRTI class, the most frequently found mutations were K103N (5.5%; 4/73), K101E (4.1%; 3/73), G190A (4.1%; 3/73), E138Q (2.7%; 2/73), and Y181C (1.4%; 1/73). For the NRTI class, the most frequent resistance mutations were M184V (2.7%; 2/73) and T215Y (1.4%; 1/73) (<xref rid="viruses-16-01953-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec3dot4-viruses-16-01953"><title>3.4. Resistance Levels to Various ARV Drugs</title><p>The levels of resistance associated with each specific drug were based on the interpretation of the Stanford HIV database. The levels of resistance were classified into five categories: Susceptible (S), Potential Low-level Resistance (PLR), Low-Level Resistance (LLR), Intermediate Resistance (IR), and High-Level Resistance (HLR). For the NRTI class, the following mutations were found: M184V and M184V + T215Y. The M184V mutation confers HLR to Emtricitabine (FTC) and Lamivudine (3TC), and LLR to Abacavir (ABC). The combination of M184V + T215Y confers HLR to FTC and 3TC.</p><p>For the NNRTI class, the following mutations were found: K103N, K101E, E138Q, G190A, and Y181C. The K103N mutation confers HLR to doravirine (DOR), efavirenz (EFV), etravirine (ETR), nevirapine (NVP), and rilpivirine (RPV). The Y181C mutation causes IR to EFV, ETR, and RPV, and HLR to NVP. The combinations of mutations, namely K101E, K103N, and G190GA, result in HLR to NVP, RPV, and EFV, as well as IR to ETR and low-level resistance to DOR. Another identified combination, K103N and E138A, confers HLR to NVP and LLR to ETR and RPV. In the case of the combination K101E, E138Q, and G190A, there is HLR to NVP and RPV, IR to ETR, and LLR to DOR (<xref rid="viruses-16-01953-t002" ref-type="table">Table 2</xref>).</p><p>Of the two sequences with mutations associated with resistance to NRTIs, both exhibited high-level resistance to 3TC and FTC, and one showed IR to zidovudine (AZT). In the case of the seven sequences with mutations associated with NNRTIs, all of them showed HLR to NVP, while six of them (85.7%) exhibited HLR to EFV. Regarding RPV, three sequences (42.9%) showed HLR. Notably, for DOR, only LLR or PLLR was identified (<xref rid="viruses-16-01953-f005" ref-type="fig">Figure 5</xref>).</p></sec><sec id="sec3dot5-viruses-16-01953"><title>3.5. Factors Associated with the Presence of Mutations Associated with Antiretroviral Resistance</title><p>None of the analyzed sociodemographic and clinical variables was significantly associated with the occurrence of TDR mutations (<italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="viruses-16-01953-t003" ref-type="table">Table 3</xref>). However, TDR mutations were more common among men than women (5.5% versus 4.1%, <italic toggle="yes">p</italic> = 0.777), and participants under the age of 30 had a higher proportion of TDR compared to other age groups (5.5% vs. 2.7%, <italic toggle="yes">p</italic> = 0.273). Employed individuals had higher proportions of TDR compared to unemployed individuals and students (6.8% versus 1.4%, OR = 2.36, 95% CI 0.23&#x02013;24.33, <italic toggle="yes">p</italic> = 0.471; 6.8% versus 1.4%, OR = 5.9, 95% CI 0.45&#x02013;76.95, <italic toggle="yes">p</italic> = 0.176). It was observed that the majority of participants (34 out of 60, or 56.7%) had CD<sup>4+</sup> T cell counts below 350 cells/mm<sup>3</sup> at the time of diagnosis, indicating a late diagnosis of HIV-1 infection. Furthermore, individuals with CD<sup>4+</sup> T cell counts below 350 cells/mm<sup>3</sup> presented with TDR more frequently compared to those with CD<sup>4+</sup> T cell counts between 350 and 499 cells/mm<sup>3</sup> (5.5% vs. 1.4% OR = 0.625, 95% CI 0.063&#x02013;6.180, <italic toggle="yes">p</italic> = 0.688). The prevalence of TDR was higher among participants with HIV-1 recombinant subtype CRF02_AG compared to those with subtype G (5.5% versus 4.1%, OR = 1.231, IC 95% 0.25&#x02013;6.07, <italic toggle="yes">p</italic> = 0.799). The sample size in this study was small, which may have limited the detection of statistically significant differences.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01953"><title>4. Discussion</title><p>In this study, we used a genomic surveillance approach combined with sociodemographic and clinical questionnaires to characterize a population of newly diagnosed HIV-1-infected drug-na&#x000ef;ve individuals from Cabo Verde, including individuals from the islands of S&#x000e3;o Vicente, Boavista, Fogo, and Santiago. From previous reports, it was known that the islands of Santiago (70.6%), S&#x000e3;o Vicente (11.7%), Fogo (5.1%), and Boa Vista (1.5%) together account for more than 85% of the PLHIV in the country [<xref rid="B16-viruses-16-01953" ref-type="bibr">16</xref>]. We also found that HIV-1 subtypes are unevenly distributed among the Cabo Verdean islands. The results of our study reveal that the majority of newly diagnosed participants (46.6%) were in the age group of 31 to 50 years. This age distribution is in line with previous studies carried out in the country [<xref rid="B15-viruses-16-01953" ref-type="bibr">15</xref>,<xref rid="B24-viruses-16-01953" ref-type="bibr">24</xref>]. The spread of this infection among young people highlights the importance of developing prevention programmes targeted to this specific group. Of the various routes of HIV transmission, the sexual route is the most common and is responsible for almost 70% of HIV-1 infections globally [<xref rid="B27-viruses-16-01953" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01953" ref-type="bibr">28</xref>]. Consistently, in our study, HIV-1 infection was reported to be transmitted mainly by sexual route (91.8%). These data are consistent with other studies performed in the country and globally [<xref rid="B29-viruses-16-01953" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01953" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01953" ref-type="bibr">31</xref>].</p><p>The HIV-1 genome presents high levels of genetic diversity and has diverged into different subtypes and recombinant forms. In this study, it was possible to identify the presence of five distinct HIV-1 pure subtypes (A, B, C, F, and G), as well as of a circulating recombinant form (CRF02_AG). The recombinant form CRF02_AG (41.1%) was the most prevalent variant identified in this population, followed by subtype G (37.0%). These results are consistent with other studies conducted in the country [<xref rid="B23-viruses-16-01953" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01953" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01953" ref-type="bibr">25</xref>], which also reported a predominance of CRF02_AG. However, the prevalence of the CRF02_AG found in our study was even higher than that reported in previous studies, indicating that CRF02_AG might be becoming dominant. These results are also consistent with the molecular profile of HIV-1 in other West African countries neighbouring Cabo Verde, namely Guinea Bissau and Senegal [<xref rid="B32-viruses-16-01953" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01953" ref-type="bibr">33</xref>,<xref rid="B34-viruses-16-01953" ref-type="bibr">34</xref>]. CRF02_AG is, in fact, one of the most prevalent recombinant HIV-1 strains globally, with an estimated proportion of 7.7% of infections worldwide [<xref rid="B35-viruses-16-01953" ref-type="bibr">35</xref>] and a clear predominance in West African countries [<xref rid="B36-viruses-16-01953" ref-type="bibr">36</xref>]. This pattern may be due to the early exportation of the CRF or the parental subtypes to this region of Africa after the early ignition of the HIV-1 epidemic in Central Africa. Its global prevalence may also be explained by its greater in vitro replicative capacity compared to other subtypes [<xref rid="B37-viruses-16-01953" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01953" ref-type="bibr">38</xref>]. However, its recombinant origin is still debated, given reports indicating a potential pure origin for this CRF [<xref rid="B39-viruses-16-01953" ref-type="bibr">39</xref>] and a recombinant origin for its parental subtype G.</p><p>The island of Santiago seems to be a hub for HIV-1 in Cabo Verde, as it stands out as exhibiting the broadest genetic diversity, with all the subtypes covered in this study identified there, except for subtype F, which was found exclusively on the island of S&#x000e3;o Vicente. This remarkable genetic variability observed on the island of Santiago may be associated with the fact that it is the largest island in Cabo Verde, home to more than half of the country&#x02019;s population [<xref rid="B14-viruses-16-01953" ref-type="bibr">14</xref>], and where the capital Praia is situated. Due to its socioeconomic development, it has a high influx of people from different regions of the country and other parts of the world. This population mobility may be one of the main reasons for the increased genetic diversity of HIV-1 on Santiago Island compared to other islands. Population movements have long been recognized as a major contributor to the dissemination of HIV-1 on a global scale [<xref rid="B40-viruses-16-01953" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01953" ref-type="bibr">41</xref>,<xref rid="B42-viruses-16-01953" ref-type="bibr">42</xref>].</p><p>In our study, subtype F was identified exclusively on the island of S&#x000e3;o Vicente, in line with other previous studies [<xref rid="B24-viruses-16-01953" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01953" ref-type="bibr">25</xref>]. These data highlight the consistent presence of subtype F on the island over time. The exclusivity of subtype F on this island raises questions about its origin and potential transmission routes. Despite exhibiting a relatively low global prevalence (&#x0003c;1%) [<xref rid="B35-viruses-16-01953" ref-type="bibr">35</xref>], subtype F has been identified in various regions, including Central Africa, South America, and Europe, in both its non-recombinant form and as part of recombinant genomes [<xref rid="B43-viruses-16-01953" ref-type="bibr">43</xref>,<xref rid="B44-viruses-16-01953" ref-type="bibr">44</xref>]. The detection of this specific subtype in S&#x000e3;o Vicente emphasizes the need for phylodynamic studies to understand the origin and transmission dynamics of HIV-1 subtype F in this island.</p><p>The presence of several HIV-1 subtypes considerably increases the likelihood of occurrence of intersubtype recombination events, culminating in the generation of new recombinant forms, either circulating recombinant forms (CRFs) or unique recombinant forms (URFs). The surveillance and monitoring of the genetic evolution of HIV-1 are essential for understanding and addressing the complex issues posed by its diversity, as well as for developing effective prevention and treatment approaches in the ongoing fight against the HIV/AIDS pandemic. This study confirmed a significant association (<italic toggle="yes">p</italic> &#x0003c; 0.05) between the distribution of viral subtypes and the island of residence of the infected individuals. The high level of tourism in Cabo Verde and the associated migratory flows may serve as potential routes for the introduction of different variants of the virus. In addition, the country&#x02019;s geographical location, as a point of intersection between the continents of Europe, America, and Africa, raises the possibility that the country may be a hub with an inflow of HIV-1 subtypes from these different geographic regions. Further studies are needed to better understand these phenomena.</p><p>This study found a moderate prevalence (9.6%) of TDR in Cabo Verde, according to the definition of the WHO [<xref rid="B45-viruses-16-01953" ref-type="bibr">45</xref>]. However, this value is higher than that found in the last study conducted in the country (3.4%) [<xref rid="B24-viruses-16-01953" ref-type="bibr">24</xref>], and follows the trend observed in many countries in sub-Saharan Africa and in resource-limited countries, where TDR levels exceed 10% [<xref rid="B34-viruses-16-01953" ref-type="bibr">34</xref>,<xref rid="B46-viruses-16-01953" ref-type="bibr">46</xref>]. The rapid increase in TDR in these countries is caused by the ARV scale-up without the associated routine surveillance of TDR in newly diagnosed patients and without resources to test for ARV DR in patients failing therapy. These factors can contribute to the persistence of high viral loads in patients left without a diagnosis of treatment failure, which can then be transmitted to other patients.</p><p>The prevalence of mutations associated with NRTIs and NNRTIs was 2.75% (n = 2) and 9.7% (n = 7), respectively. Among the most prevalent mutations, K103N was highlighted among the NNRTIs and M184V among the NRTIs. These mutations were also identified in other studies conducted in country [<xref rid="B23-viruses-16-01953" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01953" ref-type="bibr">24</xref>] and in several countries in West Africa and around the world [<xref rid="B47-viruses-16-01953" ref-type="bibr">47</xref>,<xref rid="B48-viruses-16-01953" ref-type="bibr">48</xref>]. These data are particularly concerning as the K103N mutation is a non-polymorphic genetic mutation that confers resistance to NNRTIs, such as NVP and EFV [<xref rid="B49-viruses-16-01953" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01953" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01953" ref-type="bibr">51</xref>]. Studies have shown that this mutation can reduce susceptibility to NVP and EFV by approximately 50 and 20 times, respectively [<xref rid="B52-viruses-16-01953" ref-type="bibr">52</xref>,<xref rid="B53-viruses-16-01953" ref-type="bibr">53</xref>]. It is important to highlight that K103N is the most frequently observed and transmitted drug resistance mutation [<xref rid="B54-viruses-16-01953" ref-type="bibr">54</xref>]. On the other hand, the M184V mutation is associated with high-level resistance to 3TC and FTC, resulting in a susceptibility reduction to these drugs of more than 200 times [<xref rid="B55-viruses-16-01953" ref-type="bibr">55</xref>,<xref rid="B56-viruses-16-01953" ref-type="bibr">56</xref>]. While DRMs to NNRTIs are not so worrying, as this drug class is barely used currently in the country, M184V in particular should be monitored closely, since it confers resistance to drugs that are currently used as the first-line regimen in Cabo Verde. The currently used first-line regimen is TDF + 3TC + DTG. Baseline resistance to one of the NRTIs in the regimen&#x02014;in this case, 3TC&#x02014;can threaten the efficacy of DTG, which is then used in a context comparable to dual therapy.</p><p>When comparing our data with studies conducted in neighbouring countries, namely Senegal and Guinea-Bissau [<xref rid="B33-viruses-16-01953" ref-type="bibr">33</xref>,<xref rid="B57-viruses-16-01953" ref-type="bibr">57</xref>,<xref rid="B58-viruses-16-01953" ref-type="bibr">58</xref>], we observed a high rate of TDR. According to these authors, this resistance can accelerate the spread of resistant strains, compromising the efficacy of available therapies and associating these mutations with high rates of virological failure. These studies demonstrate that continuous surveillance is essential to ensure the success of treatment and prevent the spread of resistant strains. TDR to HIV-1 not only compromises the efficacy of treatments, but also presents significant challenges for controlling the epidemic. Therefore, it is imperative that public health policies in Cabo Verde consider this evidence when developing treatment interventions, aiming to optimize clinical outcomes and contain the spread of the virus.</p><p>No mutations associated with PIs and INSTIs were detected. This absence may be related to the low use of these ART classes in the currently recommended treatment regimens in the country. With the widespread introduction of DTG and the second-line use of PIs, the emergence of resistance mutations to these drug classes may occur.</p><p>Finally, the obtained results indicated the absence of significant associations between sociodemographic and clinical variables and the presence of mutations associated with ARV resistance (<xref rid="viruses-16-01953-t003" ref-type="table">Table 3</xref>). These findings suggest that such variables do not play a significant role in the occurrence of resistance mutations. It is important to note that the sample size was relatively small, which may have limited the detection of statistically relevant differences. Therefore, future studies with a larger sample have the potential to provide a deeper understanding of this issue.</p><p>Routine TDR monitoring is crucial to assess the emergence and spread of DRMs. Due to the increasing resistance to NNRTIs, the WHO recommended the use of DTG as the first-line treatment regimen for people living with HIV [<xref rid="B21-viruses-16-01953" ref-type="bibr">21</xref>]. In addition to providing effective viral suppression, it presents a high genetic barrier to the development of HIV resistance, making it a crucial choice in the treatment of this condition [<xref rid="B59-viruses-16-01953" ref-type="bibr">59</xref>,<xref rid="B60-viruses-16-01953" ref-type="bibr">60</xref>,<xref rid="B61-viruses-16-01953" ref-type="bibr">61</xref>]. In Cabo Verde, since 2019, the introduction of DTG into the first-line treatment regimen, along with lamivudine and tenofovir, has been gradually implemented. This measure is already in place in the country. However, in order to ensure the sustained effectiveness of this regimen, it is crucial to implement an effective routine system for epidemiological surveillance of antiretroviral resistance. Otherwise, the use of this drug class as first-line treatment could be threatened in the short term by the emergence of DRMs.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01953"><title>5. Conclusions</title><p>The genetic diversity of HIV-1 in Cabo Verde is dominated by CRF02_AG and subtype G. The prevalence of TDR in the country is close to 10%, which may impact the effectiveness of treatment. No mutations associated with the PI and INSTI classes were identified, suggesting that antiretroviral regimens from these classes remain effective in the country. However, given the predicted increase in drug resistance to first-line drug classes, the implementation of routine HIV drug resistance surveillance is crucial to ensure the continued effectiveness of these drugs.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all clinical and technical support and support received from the Cape Verdean professionals who made this study possible. We deeply thank all the doctors, nurses, laboratory technicians, and healthcare professionals who played a crucial role in collecting and providing the data for this study: Maria Ros&#x000e1;rio, Elsa Almeida, Idelmira Horta, Kr&#x000ed;sia Delgado, Suzete Costa, Risete Gomes, Elisangela Tavares, Dulce Veiga, Diva Borges, Raquel Ramos, Euridice Lima, Antonia Oliveira, Jacqueline Cid, Joana Alves, nurse Luc&#x000ed;lia Levy, Cesarina Cruz, and Celivianne Sousa. Special thanks go to the patients who agreed to participate in this study. We thank the National Institute of Public Health (INSP) of Cabo Verde for support. We thank Jonas Gomes and Adnilson Medina, from the INSP, for the map drawing. Special thanks go to the Cam&#x000f5;es Foundation and Millennium BCP Bank for funding a scholarship to Silvania Leal.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>A.B.A., S.D.V.L., M.P., R.P. and I.I.M.d.P.A. designed this study and wrote the ethics committee protocol. S.D.V.L. was responsible for questionnaire application and collected patient samples. S.D.V.L., P.G. and N.T. performed the molecular laboratory work. S.D.V.L., V.P., M.P. and A.B.A. analyzed genomic and epidemiologic data. S.D.V.L. wrote the original draft of the manuscript. S.D.V.L., A.B.A., R.P., N.T., P.G., M.P., V.P. and I.I.M.d.P.A. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Ministry of Health of Cabo Verde (Reference no. 13/2018, on 3 may 2018).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. ABA, VP, and MP declare that they have performed consultancy work for ViiV HealthCare.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01953"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>UNAIDS</collab>
</person-group><article-title>Global HIV Statistics Fact Sheet</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf" ext-link-type="uri">https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-29">(accessed on 29 March 2023)</date-in-citation></element-citation></ref><ref id="B2-viruses-16-01953"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>HIV/AIDS: Key facts. In World Health Organisation</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/key-facts-hiv-2021-26july2022.pdf?sfvrsn=8f4e7c93_5" ext-link-type="uri">https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/key-facts-hiv-2021-26july2022.pdf?sfvrsn=8f4e7c93_5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-10-19">(accessed on 19 October 2023)</date-in-citation></element-citation></ref><ref id="B3-viruses-16-01953"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arimide</surname><given-names>D.A.</given-names></name>
<name><surname>Abebe</surname><given-names>A.</given-names></name>
<name><surname>Kebede</surname><given-names>Y.</given-names></name>
<name><surname>Adugna</surname><given-names>F.</given-names></name>
<name><surname>Tilahun</surname><given-names>T.</given-names></name>
<name><surname>Kassa</surname><given-names>D.</given-names></name>
<name><surname>Assefa</surname><given-names>Y.</given-names></name>
<name><surname>Balcha</surname><given-names>T.T.</given-names></name>
<name><surname>Bj&#x000f6;rkman</surname><given-names>P.</given-names></name>
<name><surname>Medstrand</surname><given-names>P.</given-names></name>
</person-group><article-title>HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003&#x02013;2013</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0205446</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0205446</pub-id><pub-id pub-id-type="pmid">30304061</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01953"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu&#x000e9;</surname><given-names>S.</given-names></name>
<name><surname>Gifford</surname><given-names>R.J.</given-names></name>
<name><surname>Dunn</surname><given-names>D.</given-names></name>
<name><surname>Fernhill</surname><given-names>E.</given-names></name>
<name><surname>Pillay</surname><given-names>D.</given-names></name>
</person-group><article-title>Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Na&#x000ef;ve Individuals</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>2645</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.1128/JVI.01556-08</pub-id><pub-id pub-id-type="pmid">19158238</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01953"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mourad</surname><given-names>R.</given-names></name>
<name><surname>Chevennet</surname><given-names>F.</given-names></name>
<name><surname>Dunn</surname><given-names>D.T.</given-names></name>
<name><surname>Fearnhill</surname><given-names>E.</given-names></name>
<name><surname>Delpech</surname><given-names>V.</given-names></name>
<name><surname>Asboe</surname><given-names>D.</given-names></name>
<name><surname>Gascuel</surname><given-names>O.</given-names></name>
<name><surname>Hue</surname><given-names>S.</given-names></name>
<collab>UK HIV Drug Resistance Database &#x00026; The Collaborative HIV, Anti-HIV Drug Resistance Network</collab>
</person-group><article-title>A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK</article-title><source>AIDS Lond. Engl.</source><year>2015</year><volume>29</volume><fpage>1917</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000768</pub-id><pub-id pub-id-type="pmid">26355570</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01953"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhukova</surname><given-names>A.</given-names></name>
<name><surname>Cutino-Moguel</surname><given-names>T.</given-names></name>
<name><surname>Gascuel</surname><given-names>O.</given-names></name>
<name><surname>Pillay</surname><given-names>D.</given-names></name>
</person-group><article-title>The Role of Phylogenetics as a Tool to Predict the Spread of Resistance</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>S820</fpage><lpage>S823</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix411</pub-id><pub-id pub-id-type="pmid">29029155</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01953"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillay</surname><given-names>D.</given-names></name>
<name><surname>Bhaskaran</surname><given-names>K.</given-names></name>
<name><surname>Jurriaans</surname><given-names>S.</given-names></name>
<name><surname>Prins</surname><given-names>M.</given-names></name>
<name><surname>Masquelier</surname><given-names>B.</given-names></name>
<name><surname>Dabis</surname><given-names>F.</given-names></name>
<name><surname>Gifford</surname><given-names>R.</given-names></name>
<name><surname>Nielsen</surname><given-names>C.</given-names></name>
<name><surname>Pedersen</surname><given-names>C.</given-names></name>
<name><surname>Balotta</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy</article-title><source>AIDS Lond. Engl.</source><year>2006</year><volume>20</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000196172.35056.b7</pub-id></element-citation></ref><ref id="B8-viruses-16-01953"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simen</surname><given-names>B.B.</given-names></name>
<name><surname>Simons</surname><given-names>J.F.</given-names></name>
<name><surname>Hullsiek</surname><given-names>K.H.</given-names></name>
<name><surname>Novak</surname><given-names>R.M.</given-names></name>
<name><surname>Macarthur</surname><given-names>R.D.</given-names></name>
<name><surname>Baxter</surname><given-names>J.D.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Lubeski</surname><given-names>C.</given-names></name>
<name><surname>Turenchalk</surname><given-names>G.S.</given-names></name>
<name><surname>Braverman</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>199</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1086/596736</pub-id><pub-id pub-id-type="pmid">19210162</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01953"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frentz</surname><given-names>D.</given-names></name>
<name><surname>Boucher</surname><given-names>C.A.B.</given-names></name>
<name><surname>van de Vijver</surname><given-names>D.A.M.C.</given-names></name>
</person-group><article-title>Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World</article-title><source>Aids Rev.</source><year>2012</year><volume>14</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">22297501</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01953"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geretti</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Epidemiology of antiretroviral drug resistance in drug-na&#x000ef;ve persons</article-title><source>Curr. Opin. Infect. Dis.</source><year>2007</year><volume>20</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e328013caff</pub-id><pub-id pub-id-type="pmid">17197878</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01953"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Little</surname><given-names>S.J.</given-names></name>
<name><surname>Holte</surname><given-names>S.</given-names></name>
<name><surname>Routy</surname><given-names>J.-P.</given-names></name>
<name><surname>Daar</surname><given-names>E.S.</given-names></name>
<name><surname>Markowitz</surname><given-names>M.</given-names></name>
<name><surname>Collier</surname><given-names>A.C.</given-names></name>
<name><surname>Koup</surname><given-names>R.A.</given-names></name>
<name><surname>Mellors</surname><given-names>J.W.</given-names></name>
<name><surname>Connick</surname><given-names>E.</given-names></name>
<name><surname>Conway</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Antiretroviral-drug resistance among patients recently infected with HIV</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>347</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa013552</pub-id><pub-id pub-id-type="pmid">12167680</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01953"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillay</surname><given-names>D.</given-names></name>
</person-group><article-title>Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe</article-title><source>Antivir. Ther.</source><year>2004</year><volume>9</volume><fpage>695</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1177/135965350400900514</pub-id><pub-id pub-id-type="pmid">15535406</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01953"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
<name><surname>Gregson</surname><given-names>J.</given-names></name>
<name><surname>Parkin</surname><given-names>N.</given-names></name>
<name><surname>Haile-Selassie</surname><given-names>H.</given-names></name>
<name><surname>Tanuri</surname><given-names>A.</given-names></name>
<name><surname>Andrade Forero</surname><given-names>L.</given-names></name>
<name><surname>Kaleebu</surname><given-names>P.</given-names></name>
<name><surname>Watera</surname><given-names>C.</given-names></name>
<name><surname>Aghokeng</surname><given-names>A.</given-names></name>
<name><surname>Mutenda</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30702-8</pub-id><pub-id pub-id-type="pmid">29198909</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01953"><label>14.</label><element-citation publication-type="webpage"><article-title>INE Censo 2021-INE</article-title><comment>Available online: <ext-link xlink:href="https://ine.cv/censo_quadros/cabo-verde-corrigido/" ext-link-type="uri">https://ine.cv/censo_quadros/cabo-verde-corrigido/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-10-03">(accessed on 3 October 2023)</date-in-citation></element-citation></ref><ref id="B15-viruses-16-01953"><label>15.</label><element-citation publication-type="webpage"><article-title>INE Inqu&#x000e9;rito Demogr&#x000e1;fico e de Sa&#x000fa;de Reprodutiva, IDSR-III, Cabo Verde 2018. Praia</article-title><year>2018</year><comment>Available online: <ext-link xlink:href="https://ine.cv/wp-content/uploads/2022/04/rapport-final_idsr-iii.pdf" ext-link-type="uri">https://ine.cv/wp-content/uploads/2022/04/rapport-final_idsr-iii.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-10-06">(accessed on 6 October 2023)</date-in-citation></element-citation></ref><ref id="B16-viruses-16-01953"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Minist&#x000e9;rio Sa&#x000fa;de</collab>
</person-group><source>V Plano Estrategico Nacional de Luta Contra a SIDA (2022&#x02013;2026)</source><publisher-name>Comit&#x000e9; de Coordena&#x000e7;&#x000e3;o do Combate &#x000e1; SIDA</publisher-name><publisher-loc>Praia, Cape Verde</publisher-loc><year>2021</year></element-citation></ref><ref id="B17-viruses-16-01953"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>MSSS</collab>
</person-group><source>Protocolo de Terap&#x000ea;utica Antirretroviral</source><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de de Cabo Verde</publisher-name><publisher-loc>Praia, Cape Verde</publisher-loc><year>2019</year></element-citation></ref><ref id="B18-viruses-16-01953"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2021</year></element-citation></ref><ref id="B19-viruses-16-01953"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2013</year><isbn>978-92-4-150572-7</isbn></element-citation></ref><ref id="B20-viruses-16-01953"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>OMS</collab>
</person-group><source>Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2015</year><isbn>978-92-4-150956-5</isbn></element-citation></ref><ref id="B21-viruses-16-01953"><label>21.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>OMS</collab>
</person-group><article-title>Update of Recommendations on First- and Second-Line Antiretroviral Regimens</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications-detail-redirect/WHO-CDS-HIV-19.15" ext-link-type="uri">https://www.who.int/publications-detail-redirect/WHO-CDS-HIV-19.15</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-10-06">(accessed on 6 October 2023)</date-in-citation></element-citation></ref><ref id="B22-viruses-16-01953"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>OMS</collab>
</person-group><source>Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines. Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2018</year></element-citation></ref><ref id="B23-viruses-16-01953"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>V.</given-names></name>
<name><surname>B&#x000e1;rtolo</surname><given-names>I.</given-names></name>
<name><surname>Borrego</surname><given-names>P.</given-names></name>
<name><surname>Rocha</surname><given-names>C.</given-names></name>
<name><surname>Valadas</surname><given-names>E.</given-names></name>
<name><surname>Barreto</surname><given-names>J.</given-names></name>
<name><surname>Almeida</surname><given-names>E.</given-names></name>
<name><surname>Antunes</surname><given-names>F.</given-names></name>
<name><surname>Taveira</surname><given-names>N.</given-names></name>
</person-group><article-title>Genetic diversity and drug resistance profiles in HIV type 1- and HIV type 2-infected patients from Cape Verde Islands</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2012</year><volume>28</volume><fpage>510</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1089/aid.2011.0174</pub-id><pub-id pub-id-type="pmid">21902592</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01953"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Pina-Araujo</surname><given-names>I.I.M.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>M.L.</given-names></name>
<name><surname>Bello</surname><given-names>G.</given-names></name>
<name><surname>Vicente</surname><given-names>A.C.P.</given-names></name>
<name><surname>Morgado</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Profile of the HIV epidemic in Cape Verde: Molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e96201</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096201</pub-id><pub-id pub-id-type="pmid">24763617</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01953"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gon&#x000e7;alves</surname><given-names>P.</given-names></name>
<name><surname>Barreto</surname><given-names>J.</given-names></name>
<name><surname>Santos</surname><given-names>M.</given-names></name>
<name><surname>Leal</surname><given-names>S.</given-names></name>
<name><surname>Marcelino</surname><given-names>J.</given-names></name>
<name><surname>Abecasis</surname><given-names>A.</given-names></name>
<name><surname>Palladino</surname><given-names>C.</given-names></name>
<name><surname>Taveira</surname><given-names>N.</given-names></name>
</person-group><article-title>HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde, 2019&#x02013;2021</article-title><source>AIDS Lond. Engl.</source><year>2024</year><volume>38</volume><fpage>1101</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003866</pub-id><pub-id pub-id-type="pmid">38349224</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01953"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanger</surname><given-names>F.</given-names></name>
<name><surname>Nicklen</surname><given-names>S.</given-names></name>
<name><surname>Coulson</surname><given-names>A.R.</given-names></name>
</person-group><article-title>DNA sequencing with chain-terminating inhibitors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1977</year><volume>74</volume><fpage>5463</fpage><lpage>5467</lpage><pub-id pub-id-type="doi">10.1073/pnas.74.12.5463</pub-id><pub-id pub-id-type="pmid">271968</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01953"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hladik</surname><given-names>F.</given-names></name>
<name><surname>McElrath</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Setting the stage: Host invasion by HIV</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>447</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nri2302</pub-id><pub-id pub-id-type="pmid">18469831</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01953"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McElrath</surname><given-names>M.J.</given-names></name>
<name><surname>De Rosa</surname><given-names>S.C.</given-names></name>
<name><surname>Moodie</surname><given-names>Z.</given-names></name>
<name><surname>Dubey</surname><given-names>S.</given-names></name>
<name><surname>Kierstead</surname><given-names>L.</given-names></name>
<name><surname>Janes</surname><given-names>H.</given-names></name>
<name><surname>Defawe</surname><given-names>O.D.</given-names></name>
<name><surname>Carter</surname><given-names>D.K.</given-names></name>
<name><surname>Hural</surname><given-names>J.</given-names></name>
<name><surname>Akondy</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1894</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61592-5</pub-id><pub-id pub-id-type="pmid">19012957</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01953"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kharsany</surname><given-names>A.B.M.</given-names></name>
<name><surname>Karim</surname><given-names>Q.A.</given-names></name>
</person-group><article-title>HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities</article-title><source>Open AIDS J.</source><year>2016</year><volume>10</volume><fpage>34</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.2174/1874613601610010034</pub-id><pub-id pub-id-type="pmid">27347270</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01953"><label>30.</label><element-citation publication-type="book"><source>UNAIDS The Path That Ends AIDS: UNAIDS Global AIDS Update 2023</source><publisher-name>Joint United Nations Programme on HIV/AIDS</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2023</year></element-citation></ref><ref id="B31-viruses-16-01953"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeziulin</surname><given-names>O.</given-names></name>
<name><surname>Kornilova</surname><given-names>M.</given-names></name>
<name><surname>Deac</surname><given-names>A.</given-names></name>
<name><surname>Morozova</surname><given-names>O.</given-names></name>
<name><surname>Varetska</surname><given-names>O.</given-names></name>
<name><surname>Pykalo</surname><given-names>I.</given-names></name>
<name><surname>Dumchev</surname><given-names>K.</given-names></name>
</person-group><article-title>Modes of HIV transmission among young women and their sexual partners in Ukraine</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><elocation-id>e0305072</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0305072</pub-id><pub-id pub-id-type="pmid">38923979</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01953"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hemelaar</surname><given-names>J.</given-names></name>
<name><surname>Gouws</surname><given-names>E.</given-names></name>
<name><surname>Ghys</surname><given-names>P.D.</given-names></name>
<name><surname>Osmanov</surname><given-names>S.</given-names></name>
</person-group><article-title>Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004</article-title><source>AIDS Lond. Engl.</source><year>2006</year><volume>20</volume><fpage>W13</fpage><lpage>W23</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000247564.73009.bc</pub-id></element-citation></ref><ref id="B33-viruses-16-01953"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mbange</surname><given-names>A.E.</given-names></name>
<name><surname>Kaba</surname><given-names>D.</given-names></name>
<name><surname>Diouara</surname><given-names>A.A.M.</given-names></name>
<name><surname>Diop-Ndiaye</surname><given-names>H.</given-names></name>
<name><surname>Ngom-Ngueye</surname><given-names>N.F.</given-names></name>
<name><surname>Dieng</surname><given-names>A.</given-names></name>
<name><surname>Lo</surname><given-names>S.</given-names></name>
<name><surname>Toure</surname><given-names>K.N.</given-names></name>
<name><surname>Fall</surname><given-names>M.</given-names></name>
<name><surname>Mbacham</surname><given-names>W.F.</given-names></name>
<etal/>
</person-group><article-title>Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea</article-title><source>BMC Res. Notes</source><year>2018</year><volume>11</volume><elocation-id>723</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-018-3804-9</pub-id><pub-id pub-id-type="pmid">30309385</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01953"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilhelmson</surname><given-names>S.</given-names></name>
<name><surname>M&#x000e5;nsson</surname><given-names>F.</given-names></name>
<name><surname>Lindman</surname><given-names>J.L.</given-names></name>
<name><surname>Biai</surname><given-names>A.</given-names></name>
<name><surname>Esbj&#x000f6;rnsson</surname><given-names>J.</given-names></name>
<name><surname>Norrgren</surname><given-names>H.</given-names></name>
<name><surname>Jansson</surname><given-names>M.</given-names></name>
<name><surname>Medstrand</surname><given-names>P.</given-names></name>
<collab>SWEGUB CORE Group</collab>
</person-group><article-title>Prevalence of HIV-1 pretreatment drug resistance among treatment na&#x000ef;ve pregnant women in Bissau, Guinea Bissau</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0206406</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0206406</pub-id><pub-id pub-id-type="pmid">30379960</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01953"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hemelaar</surname><given-names>J.</given-names></name>
<name><surname>Elangovan</surname><given-names>R.</given-names></name>
<name><surname>Yun</surname><given-names>J.</given-names></name>
<name><surname>Dickson-Tetteh</surname><given-names>L.</given-names></name>
<name><surname>Fleminger</surname><given-names>I.</given-names></name>
<name><surname>Kirtley</surname><given-names>S.</given-names></name>
<name><surname>Williams</surname><given-names>B.</given-names></name>
<name><surname>Gouws-Williams</surname><given-names>E.</given-names></name>
<name><surname>Ghys</surname><given-names>P.D.</given-names></name>
<collab>WHO&#x02013;UNAIDS Network for HIV Isolation Characterisation</collab>
</person-group><article-title>Global and regional molecular epidemiology of HIV-1, 1990&#x02013;2015: A systematic review, global survey, and trend analysis</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30647-9</pub-id><pub-id pub-id-type="pmid">30509777</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01953"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elangovan</surname><given-names>R.</given-names></name>
<name><surname>Jenks</surname><given-names>M.</given-names></name>
<name><surname>Yun</surname><given-names>J.</given-names></name>
<name><surname>Dickson-Tetteh</surname><given-names>L.</given-names></name>
<name><surname>Kirtley</surname><given-names>S.</given-names></name>
<name><surname>Hemelaar</surname><given-names>J.</given-names></name>
</person-group><article-title>Global and Regional Estimates for Subtype-Specific Therapeutic and Prophylactic HIV-1 Vaccines: A Modeling Study</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>690647</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.690647</pub-id><pub-id pub-id-type="pmid">34335516</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01953"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischetti</surname><given-names>L.</given-names></name>
<name><surname>Opare-Sem</surname><given-names>O.</given-names></name>
<name><surname>Candotti</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Allain</surname><given-names>J.-P.</given-names></name>
</person-group><article-title>Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana</article-title><source>AIDS Lond. Engl.</source><year>2004</year><volume>18</volume><fpage>1208</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1097/00002030-200405210-00017</pub-id><pub-id pub-id-type="pmid">15166539</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01953"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Njai</surname><given-names>H.F.</given-names></name>
<name><surname>Gali</surname><given-names>Y.</given-names></name>
<name><surname>Vanham</surname><given-names>G.</given-names></name>
<name><surname>Clybergh</surname><given-names>C.</given-names></name>
<name><surname>Jennes</surname><given-names>W.</given-names></name>
<name><surname>Vidal</surname><given-names>N.</given-names></name>
<name><surname>Butel</surname><given-names>C.</given-names></name>
<name><surname>Mpoudi-Ngolle</surname><given-names>E.</given-names></name>
<name><surname>Peeters</surname><given-names>M.</given-names></name>
<name><surname>Ari&#x000eb;n</surname><given-names>K.K.</given-names></name>
</person-group><article-title>The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness</article-title><source>Retrovirology</source><year>2006</year><volume>3</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-3-40</pub-id><pub-id pub-id-type="pmid">16817969</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01953"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abecasis</surname><given-names>A.B.</given-names></name>
<name><surname>Lemey</surname><given-names>P.</given-names></name>
<name><surname>Vidal</surname><given-names>N.</given-names></name>
<name><surname>de Oliveira</surname><given-names>T.</given-names></name>
<name><surname>Peeters</surname><given-names>M.</given-names></name>
<name><surname>Camacho</surname><given-names>R.</given-names></name>
<name><surname>Shapiro</surname><given-names>B.</given-names></name>
<name><surname>Rambaut</surname><given-names>A.</given-names></name>
<name><surname>Vandamme</surname><given-names>A.-M.</given-names></name>
</person-group><article-title>Recombination Confounds the Early Evolutionary History of Human Immunodeficiency Virus Type 1: Subtype G Is a Circulating Recombinant Form</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>8543</fpage><lpage>8551</lpage><pub-id pub-id-type="doi">10.1128/JVI.00463-07</pub-id><pub-id pub-id-type="pmid">17553886</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01953"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faria</surname><given-names>N.R.</given-names></name>
<name><surname>Rambaut</surname><given-names>A.</given-names></name>
<name><surname>Suchard</surname><given-names>M.A.</given-names></name>
<name><surname>Baele</surname><given-names>G.</given-names></name>
<name><surname>Bedford</surname><given-names>T.</given-names></name>
<name><surname>Ward</surname><given-names>M.J.</given-names></name>
<name><surname>Tatem</surname><given-names>A.J.</given-names></name>
<name><surname>Sousa</surname><given-names>J.D.</given-names></name>
<name><surname>Arinaminpathy</surname><given-names>N.</given-names></name>
<name><surname>P&#x000e9;pin</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.1256739</pub-id><pub-id pub-id-type="pmid">25278604</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01953"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perrin</surname><given-names>L.</given-names></name>
<name><surname>Kaiser</surname><given-names>L.</given-names></name>
<name><surname>Yerly</surname><given-names>S.</given-names></name>
</person-group><article-title>Travel and the spread of HIV-1 genetic variants</article-title><source>Lancet Infect. Dis.</source><year>2003</year><volume>3</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(03)00484-5</pub-id><pub-id pub-id-type="pmid">12505029</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01953"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomson</surname><given-names>M.M.</given-names></name>
<name><surname>N&#x000e1;jera</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: An update</article-title><source>AIDS Rev.</source><year>2005</year><volume>7</volume><fpage>210</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">16425961</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01953"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abecasis</surname><given-names>A.</given-names></name>
<name><surname>Paraskevis</surname><given-names>D.</given-names></name>
<name><surname>Epalanga</surname><given-names>M.</given-names></name>
<name><surname>Fonseca</surname><given-names>M.</given-names></name>
<name><surname>Burity</surname><given-names>F.</given-names></name>
<name><surname>Bartolomeu</surname><given-names>J.</given-names></name>
<name><surname>Carvalho</surname><given-names>A.P.</given-names></name>
<name><surname>Gomes</surname><given-names>P.</given-names></name>
<name><surname>Vandamme</surname><given-names>A.-M.</given-names></name>
<name><surname>Camacho</surname><given-names>R.</given-names></name>
</person-group><article-title>HIV-1 genetic variants circulation in the North of Angola</article-title><source>Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis.</source><year>2005</year><volume>5</volume><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2004.07.007</pub-id><pub-id pub-id-type="pmid">15737914</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01953"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guimar&#x000e3;es</surname><given-names>M.L.</given-names></name>
<name><surname>Vicente</surname><given-names>A.C.P.</given-names></name>
<name><surname>Otsuki</surname><given-names>K.</given-names></name>
<name><surname>da Silva</surname><given-names>R.F.F.</given-names></name>
<name><surname>Francisco</surname><given-names>M.</given-names></name>
<name><surname>da Silva</surname><given-names>F.G.</given-names></name>
<name><surname>Serrano</surname><given-names>D.</given-names></name>
<name><surname>Morgado</surname><given-names>M.G.</given-names></name>
<name><surname>Bello</surname><given-names>G.</given-names></name>
</person-group><article-title>Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates</article-title><source>Retrovirology</source><year>2009</year><volume>6</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-6-39</pub-id><pub-id pub-id-type="pmid">19386115</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01953"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>D.E.</given-names></name>
<name><surname>Myatt</surname><given-names>M.</given-names></name>
<name><surname>Bertagnolio</surname><given-names>S.</given-names></name>
<name><surname>Sutherland</surname><given-names>D.</given-names></name>
<name><surname>Gilks</surname><given-names>C.F.</given-names></name>
</person-group><article-title>Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment</article-title><source>Antivir. Ther.</source><year>2008</year><volume>13</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1177/135965350801302S04</pub-id><pub-id pub-id-type="pmid">18575189</pub-id>
</element-citation></ref><ref id="B46-viruses-16-01953"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ngo-Giang-Huong</surname><given-names>N.</given-names></name>
<name><surname>Huynh</surname><given-names>T.H.K.</given-names></name>
<name><surname>Dagnra</surname><given-names>A.Y.</given-names></name>
<name><surname>Toni</surname><given-names>T.</given-names></name>
<name><surname>Maiga</surname><given-names>A.I.</given-names></name>
<name><surname>Kania</surname><given-names>D.</given-names></name>
<name><surname>Eymard-Duvernay</surname><given-names>S.</given-names></name>
<name><surname>Peeters</surname><given-names>M.</given-names></name>
<name><surname>Soulie</surname><given-names>C.</given-names></name>
<name><surname>Peytavin</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1093/jac/dky443</pub-id><pub-id pub-id-type="pmid">30418575</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01953"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>A.</given-names></name>
<name><surname>Gao</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
</person-group><article-title>Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>718763</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.718763</pub-id><pub-id pub-id-type="pmid">34899288</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01953"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rhee</surname><given-names>S.-Y.</given-names></name>
<name><surname>Blanco</surname><given-names>J.L.</given-names></name>
<name><surname>Jordan</surname><given-names>M.R.</given-names></name>
<name><surname>Taylor</surname><given-names>J.</given-names></name>
<name><surname>Lemey</surname><given-names>P.</given-names></name>
<name><surname>Varghese</surname><given-names>V.</given-names></name>
<name><surname>Hamers</surname><given-names>R.L.</given-names></name>
<name><surname>Bertagnolio</surname><given-names>S.</given-names></name>
<name><surname>de Wit</surname><given-names>T.F.R.</given-names></name>
<name><surname>Aghokeng</surname><given-names>A.F.</given-names></name>
<etal/>
</person-group><article-title>Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis</article-title><source>PLoS Med.</source><year>2015</year><volume>12</volume><elocation-id>e1001810</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001810</pub-id><pub-id pub-id-type="pmid">25849352</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01953"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bacheler</surname><given-names>L.T.</given-names></name>
<name><surname>Anton</surname><given-names>E.D.</given-names></name>
<name><surname>Kudish</surname><given-names>P.</given-names></name>
<name><surname>Baker</surname><given-names>D.</given-names></name>
<name><surname>Bunville</surname><given-names>J.</given-names></name>
<name><surname>Krakowski</surname><given-names>K.</given-names></name>
<name><surname>Bolling</surname><given-names>L.</given-names></name>
<name><surname>Aujay</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>X.V.</given-names></name>
<name><surname>Ellis</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy</article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>2475</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.9.2475-2484.2000</pub-id><pub-id pub-id-type="pmid">10952598</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01953"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gulick</surname><given-names>R.M.</given-names></name>
<name><surname>Ribaudo</surname><given-names>H.J.</given-names></name>
<name><surname>Shikuma</surname><given-names>C.M.</given-names></name>
<name><surname>Lustgarten</surname><given-names>S.</given-names></name>
<name><surname>Squires</surname><given-names>K.E.</given-names></name>
<name><surname>Meyer</surname><given-names>W.A.</given-names></name>
<name><surname>Acosta</surname><given-names>E.P.</given-names></name>
<name><surname>Schackman</surname><given-names>B.R.</given-names></name>
<name><surname>Pilcher</surname><given-names>C.D.</given-names></name>
<name><surname>Murphy</surname><given-names>R.L.</given-names></name>
<etal/>
</person-group><article-title>Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>1850</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa031772</pub-id><pub-id pub-id-type="pmid">15115831</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01953"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Margot</surname><given-names>N.A.</given-names></name>
<name><surname>Lu</surname><given-names>B.</given-names></name>
<name><surname>Cheng</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>M.D.</given-names></name>
<collab>Study 903 Team</collab>
</person-group><article-title>Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903</article-title><source>HIV Med.</source><year>2006</year><volume>7</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1293.2006.00404.x</pub-id><pub-id pub-id-type="pmid">16925730</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01953"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuritzkes</surname><given-names>D.R.</given-names></name>
<name><surname>Lalama</surname><given-names>C.M.</given-names></name>
<name><surname>Ribaudo</surname><given-names>H.J.</given-names></name>
<name><surname>Marcial</surname><given-names>M.</given-names></name>
<name><surname>Meyer</surname><given-names>W.A.</given-names></name>
<name><surname>Shikuma</surname><given-names>C.</given-names></name>
<name><surname>Johnson</surname><given-names>V.A.</given-names></name>
<name><surname>Fiscus</surname><given-names>S.A.</given-names></name>
<name><surname>D&#x02019;Aquila</surname><given-names>R.T.</given-names></name>
<name><surname>Schackman</surname><given-names>B.R.</given-names></name>
<etal/>
</person-group><article-title>Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects</article-title><source>J. Infect. Dis.</source><year>2008</year><volume>197</volume><fpage>867</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1086/528802</pub-id><pub-id pub-id-type="pmid">18269317</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01953"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McClung</surname><given-names>R.P.</given-names></name>
<name><surname>Oster</surname><given-names>A.M.</given-names></name>
<name><surname>Ocfemia</surname><given-names>M.C.B.</given-names></name>
<name><surname>Saduvala</surname><given-names>N.</given-names></name>
<name><surname>Heneine</surname><given-names>W.</given-names></name>
<name><surname>Johnson</surname><given-names>J.A.</given-names></name>
<name><surname>Hernandez</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014&#x02013;2018</article-title><source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source><year>2021</year><volume>74</volume><fpage>1055</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab583</pub-id><pub-id pub-id-type="pmid">34175948</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01953"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derache</surname><given-names>A.</given-names></name>
<name><surname>Iwuji</surname><given-names>C.C.</given-names></name>
<name><surname>Baisley</surname><given-names>K.</given-names></name>
<name><surname>Danaviah</surname><given-names>S.</given-names></name>
<name><surname>Marcelin</surname><given-names>A.-G.</given-names></name>
<name><surname>Calvez</surname><given-names>V.</given-names></name>
<name><surname>de Oliveira</surname><given-names>T.</given-names></name>
<name><surname>Dabis</surname><given-names>F.</given-names></name>
<name><surname>Porter</surname><given-names>K.</given-names></name>
<name><surname>Pillay</surname><given-names>D.</given-names></name>
</person-group><article-title>Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial</article-title><source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source><year>2019</year><volume>69</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy881</pub-id></element-citation></ref><ref id="B55-viruses-16-01953"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boucher</surname><given-names>C.A.</given-names></name>
<name><surname>Cammack</surname><given-names>N.</given-names></name>
<name><surname>Schipper</surname><given-names>P.</given-names></name>
<name><surname>Schuurman</surname><given-names>R.</given-names></name>
<name><surname>Rouse</surname><given-names>P.</given-names></name>
<name><surname>Wainberg</surname><given-names>M.A.</given-names></name>
<name><surname>Cameron</surname><given-names>J.M.</given-names></name>
</person-group><article-title>High-level resistance to (-) enantiomeric 2&#x02032;-deoxy-3&#x02032;-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase</article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>2231</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.10.2231</pub-id><pub-id pub-id-type="pmid">7504909</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01953"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tisdale</surname><given-names>M.</given-names></name>
<name><surname>Kemp</surname><given-names>S.D.</given-names></name>
<name><surname>Parry</surname><given-names>N.R.</given-names></name>
<name><surname>Larder</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3&#x02032;-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1993</year><volume>90</volume><fpage>5653</fpage><lpage>5656</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.12.5653</pub-id><pub-id pub-id-type="pmid">7685907</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01953"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jespersen</surname><given-names>S.</given-names></name>
<name><surname>Tolstrup</surname><given-names>M.</given-names></name>
<name><surname>H&#x000f8;nge</surname><given-names>B.L.</given-names></name>
<name><surname>Medina</surname><given-names>C.</given-names></name>
<name><surname>T&#x000e9;</surname><given-names>D.d.S.</given-names></name>
<name><surname>Ellermann-Eriksen</surname><given-names>S.</given-names></name>
<name><surname>&#x000d8;stergaard</surname><given-names>L.</given-names></name>
<name><surname>Wejse</surname><given-names>C.</given-names></name>
<name><surname>Laursen</surname><given-names>A.L.</given-names></name>
<collab>For The Bissau HIV Cohort Study Group</collab>
</person-group><article-title>High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau</article-title><source>Virol. J.</source><year>2015</year><volume>12</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0273-9</pub-id><pub-id pub-id-type="pmid">25889017</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01953"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lindman</surname><given-names>J.</given-names></name>
<name><surname>Djalo</surname><given-names>M.A.</given-names></name>
<name><surname>Biai</surname><given-names>A.</given-names></name>
<name><surname>M&#x000e5;nsson</surname><given-names>F.</given-names></name>
<name><surname>Esbj&#x000f6;rnsson</surname><given-names>J.</given-names></name>
<name><surname>Jansson</surname><given-names>M.</given-names></name>
<name><surname>Medstrand</surname><given-names>P.</given-names></name>
<name><surname>Norrgren</surname><given-names>H.</given-names></name>
<collab>SWEGUB CORE Group</collab>
</person-group><article-title>The HIV care continuum and HIV-1 drug resistance among female sex workers: A key population in Guinea-Bissau</article-title><source>AIDS Res. Ther.</source><year>2020</year><volume>17</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12981-020-00290-3</pub-id><pub-id pub-id-type="pmid">32532294</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01953"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coffin</surname><given-names>J.</given-names></name>
<name><surname>Swanstrom</surname><given-names>R.</given-names></name>
</person-group><article-title>HIV Pathogenesis: Dynamics and Genetics of Viral Populations and Infected Cells</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2013</year><volume>3</volume><fpage>a012526</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a012526</pub-id><pub-id pub-id-type="pmid">23284080</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01953"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cottrell</surname><given-names>M.L.</given-names></name>
<name><surname>Hadzic</surname><given-names>T.</given-names></name>
<name><surname>Kashuba</surname><given-names>A.D.M.</given-names></name>
</person-group><article-title>Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir</article-title><source>Clin. Pharmacokinet.</source><year>2013</year><volume>52</volume><fpage>981</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1007/s40262-013-0093-2</pub-id><pub-id pub-id-type="pmid">23824675</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01953"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llibre</surname><given-names>J.M.</given-names></name>
<name><surname>Pulido</surname><given-names>F.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>F.</given-names></name>
<name><surname>Garc&#x000ed;a Deltoro</surname><given-names>M.</given-names></name>
<name><surname>Blanco</surname><given-names>J.L.</given-names></name>
<name><surname>Delgado</surname><given-names>R.</given-names></name>
</person-group><article-title>Genetic barrier to resistance for dolutegravir</article-title><source>AIDS Rev.</source><year>2015</year><volume>17</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">25472016</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01953-f001"><label>Figure 1</label><caption><p>Maximum likelihood (ML) phylogenetic tree analysis of 68 HIV-1 pol region nucleotide sequences collected from 2018 to 2020 in Cabo Verde. Phylogenetic analyses were performed using a comprehensive reference data set that includes all known HIV-1 group M subtypes (A, B, C, D, F, G, H, J, K) and circulating recombinant forms (CRFs: 01AE and 02AG) (N = 22) obtained from the Los Alamos HIV Sequence Database (<uri xlink:href="http://www.hiv.lanl.gov">http://www.hiv.lanl.gov</uri>, accessed on 26 September 2024). * Taxons with asterisks represent reference sequences for each subtype. Red hatched circles represent sequences harbouring some SDRM.</p></caption><graphic xlink:href="viruses-16-01953-g001" position="float"/></fig><fig position="float" id="viruses-16-01953-f002"><label>Figure 2</label><caption><p>Distribution of genetic diversity of HIV-1 subtypes in the islands of Cabo Verde.</p></caption><graphic xlink:href="viruses-16-01953-g002" position="float"/></fig><fig position="float" id="viruses-16-01953-f003"><label>Figure 3</label><caption><p>Prevalence of transmitted HIV-1 drug resistance in Cabo Verde. NRTIs: Nucleoside Reverse Transcriptase Inhibitors. NNRTIs Non-Nucleoside Reverse Transcriptase Inhibitors. TDR: transmitted HIV-1 drug resistance. PIs: protease inhibitors. NSTIs: integrase strand transfer inhibitors.</p></caption><graphic xlink:href="viruses-16-01953-g003" position="float"/></fig><fig position="float" id="viruses-16-01953-f004"><label>Figure 4</label><caption><p>Prevalence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance mutations (blue) and Nucleoside Reverse Transcriptase Inhibitor (NRTI) resistance mutations (green).</p></caption><graphic xlink:href="viruses-16-01953-g004" position="float"/></fig><fig position="float" id="viruses-16-01953-f005"><label>Figure 5</label><caption><p>Frequency and levels of HIV-1 drug resistance to various antiretroviral drugs. NRTIs: Nucleoside Reverse Transcriptase Inhibitors (3TC: lamivudine; FTC: emtricitabine; ABC: abacavir; AZT: zidovudine; TDF: tenofovir). NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors (NVP: nevirapine; EFV: efavirenz; ETR: etravirine; RPV: rilpivirine; DOR: doravirine). Red represents high-level resistance, orange represents intermediate-level resistance, blue represents low-level resistance, yellow represents potential low-level resistance, and green represents drug susceptibility.</p></caption><graphic xlink:href="viruses-16-01953-g005" position="float"/></fig><table-wrap position="float" id="viruses-16-01953-t001"><object-id pub-id-type="pii">viruses-16-01953-t001_Table 1</object-id><label>Table 1</label><caption><p>Sociodemographic, behavioural, and clinical characteristics of 73 drug-na&#x000ef;ve individuals distributed according to the HIV-1 viral subtype. The <italic toggle="yes">p</italic>-values were obtained using the chi-square test and Fisher&#x02019;s exact test.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Participant Characteristics</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Subtype CRF02_AG</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Subtype G</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Other Subtypes</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<bold><italic toggle="yes">p</italic> Value (95%)</bold>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73 (100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (41.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (37.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Sex</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35 (47.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (20.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (12.3%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.273</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (52.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (26.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (16.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (9.6%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Age group (years)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.417</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31&#x02013;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (23.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (13.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41&#x02013;50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (23.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (12.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51&#x02013;60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (20.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (9.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Island of residence</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santiago</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (75.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (31.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (32.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (11.0%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other island</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (24.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (9.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (11.0%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Occupation</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Employee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64 (87.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (35.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (31.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (20.5%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.922</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unemployed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Student</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Marital status</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Married</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (24.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (12.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.503</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (75.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (32.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (24.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Education level</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Illiterate/only literate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.254</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elementary School</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (49.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (9.6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary Education</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (32.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (13.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Mode of Transmission</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heterosexual</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67 (91.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (39.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (34.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.249</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Men who have sex with men</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (9.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.408</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66 (90.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (35.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (32.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">CD<sup>4+</sup> T-cell count at diagnosis</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean CD<sup>4+</sup> cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">344.1 &#x000b1; 248.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;350</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (46.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (19.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (12.3%)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.509</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">350&#x02013;499</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (11.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Viral load at diagnosis (log10 HIV-1 RNA copies/mL) IQR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median viral load</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51,700</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.964</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (19.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.1&#x02013;5.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;5.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (28.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (13.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (30.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (11.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (12.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="6" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Patients with co-infections</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 (45.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (8.2%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.542</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 (54.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (19.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (13.7%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-16-01953-t002"><object-id pub-id-type="pii">viruses-16-01953-t002_Table 2</object-id><label>Table 2</label><caption><p>Impact of drug resistance mutations identified in genomic sequences with TDR on susceptibility to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), as analyzed using the algorithm on the Stanford HIV database.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">HIV-1 Subtype</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">RT Mutations</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Nucleoside Reverse Transcriptase Inhibitors</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Non-Nucleoside Reverse Transcriptase Inhibitors</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRTIs</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NNRTIs</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AZT</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FTC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3TC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ETR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NVP</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPV</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRF02_AG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K103N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K101E, E138Q, G190A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRF02_AG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y181C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRF02_AG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K103N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRF02_AG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M184V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K101E, K103N, G190GA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M184V, T215Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K103N, E138A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLR</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K101E, E138Q, G190A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLR</td></tr></tbody></table><table-wrap-foot><fn><p>Legend: NRTIs&#x02014;Nucleoside Reverse Transcriptase Inhibitors; NNRTIs&#x02014;Non-Nucleoside Reverse Transcriptase Inhibitors; RT&#x02014;Reverse Transcriptase. Susceptible&#x02014;S; Potential Low-Level Resistance&#x02014;PLR; Low-Level Resistance&#x02014;LLR; Intermediate Resistance&#x02014;IR; High-Level Resistance&#x02014;HLR. ABC (abacavir), AZT (zidovudine), FTC (emtricitabine), 3TC (lamivudine), and TDF (tenofovir), DOR (doravirine), EFV (efavirenz), ETR (etravirine), NVP (nevirapine), and RPV (rilpivirine).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01953-t003"><object-id pub-id-type="pii">viruses-16-01953-t003_Table 3</object-id><label>Table 3</label><caption><p>Factors associated with the occurrence of drug resistance mutations based on logistic regression analysis. Ref&#x02014;reference category; OR&#x02014;Odds Ratio. Other islands include S&#x000e3;o Vicente, Fogo, and Boa Vista, and other modes of transmission include blood transfusions. * <italic toggle="yes">p</italic>&#x02014;values were obtained using the chi-square test and Fisher&#x02019;s test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">With TDR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Without TDR</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">* <italic toggle="yes">p</italic> Value</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">OR (95%CI)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic> Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Frequency n = 7 (9.6%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Frequency n = 66 (99.4%)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (43.8%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.777</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (46.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.255 (0.26&#x02013;6.049)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age group (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (12.3%)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.037</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31&#x02013;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (23.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 (0.00&#x02013;0.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.998</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41&#x02013;50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.141 (0.014&#x02013;0.01)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51&#x02013;60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.346 (0.05&#x02013;2.31)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.273</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 (0.00&#x02013;0.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.999</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Island of residence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other islands</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.801</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.801</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santiago</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (68.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 (0.14&#x02013;4.53)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Occupation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Employee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 (80.8%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unemployed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.36 (0.23&#x02013;24.33)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.471</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Student</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.9 (0.45&#x02013;76.95)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.176</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marital status</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (18.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 (67.1%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.673</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.511</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Married</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (23.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48 (0.05&#x02013;4.28)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Education Level</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary Education</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (30.1%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.448</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elementary School</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (42.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.774 (0.315&#x02013;9.992)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.516</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Illiterate/only literate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 (0.00&#x02013;0.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.999</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mode of transmission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heterosexual</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (9.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 (82.2%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Men who have Sex with Men</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.167 (0.406&#x02013;65.677)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.210</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 (0.00&#x02013;0.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.999</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD<sup>4+</sup> T cell count at diagnosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;350</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (41.1%)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.792</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">350&#x02013;499</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (16.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.625 (0.063&#x02013;6.180)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.688</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 (0.00&#x02013;0.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.999</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (15.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.364 (0.218&#x02013;8.523)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.740</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subtype</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 subtype G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (32.9%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.408</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRF02_AG recombinant form </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (5.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (35.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.231 (0.25&#x02013;6.07)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.799</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1subtype others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (21.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00 (000)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.998</td></tr></tbody></table></table-wrap></floats-group></article>